Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 26 Oct 2026
Standard addition

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.

Standard pembrolizumab plus lenvatinib remains the best first-line option for advanced kidney cancer, as adding other drugs didn't improve outcomes.

Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone.

What the study was

Study design
Randomized phase 3 clinical trial
Population
The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen.
Sample size
560
Category
Treatment Innovation
Maturity
Validated
Journal
Ann Oncol

Why it surfaced

Randomized phase 3 clinical trial with a PubMed abstract reviewed; the 9/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.